Cargando…

Multivalent vaccines against new SARS-CoV-2 hybrid variants

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Ghazvini, Kiarash, Keikha, Masoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212962/ https://www.ncbi.nlm.nih.gov/pubmed/35757082 http://dx.doi.org/10.1016/j.vacun.2022.06.002

Ejemplares similares

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies
por: Ghazvini, K., et al.
Publicado: (2021)

Comment on “nontuberculous mycobacterial infection after lung transplantation: a report of four cases”
por: Keikha, Masoud, et al.
Publicado: (2019)

Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?
por: Keikha, Masoud
Publicado: (2022)

Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?
por: Keikha, Masoud
Publicado: (2022)

What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies
por: Ghazvini, Kiarash, et al.
Publicado: (2021)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Comment on ‘Necrotizing fasciitis in neonate by Lichtheimia ramosa: A case study’
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned?
por: Roohani, Jalil, et al.
Publicado: (2022)

DNA-scaffolded multivalent vaccine against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2023)

Human Monkeypox resurgence 2022; a new presentation as a sexual pathogen
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Are the new SARS-CoV-2 variants resistant against the vaccine?
por: Abdalla, Mohnad, et al.
Publicado: (2021)

Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

What is the efficacy of BCG vaccination in the protection from COVID-19 in European countries?
por: Ghazvini, K., et al.
Publicado: (2021)

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
por: Zhang, Na-Na, et al.
Publicado: (2022)

Vaccination of susceptible animals against SARS-CoV-2
por: Xiang, Bin, et al.
Publicado: (2022)

Multivalent designed proteins protect against SARS-CoV-2 variants of concern
por: Hunt, Andrew C., et al.
Publicado: (2021)

Comment on “Evaluation of antibiotic resistance of Helicobacter pylori bacteria obtained from gastric biopsy samples: A cohort study”
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Social networks and human monkeypox outbreak 2022: Hazards and opportunities – Correspondence
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variants
por: Liu, Jinbiao, et al.
Publicado: (2021)

Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
por: Gao, Bo, et al.
Publicado: (2023)

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
por: Tu, Bin, et al.
Publicado: (2022)

Hashimoto encephalopathy after vaccination against SARS-CoV-2
por: Viscasillas Sancho, M., et al.
Publicado: (2022)

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Deltacron is a recombinant variant of SARS-CoV-2 but not a laboratory mistake
por: Karbalaei, Mohsen, et al.
Publicado: (2022)

Expression changes of cytotoxicity and apoptosis genes in HTLV-1-associated myelopathy/tropical spastic paraparesis patients from the perspective of system virology
por: Ghazvini, Kiarash, et al.
Publicado: (2020)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Vocal fold palsy after vaccination against SARS-CoV-2()
por: Lehrer, Eduardo, et al.
Publicado: (2022)

Chronic spontaneous urticaria following vaccination against SARS-CoV-2()
por: Zaiem, Ahmed, et al.
Publicado: (2022)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Emergence of a new SARS-CoV-2 variant in the UK
por: Tang, Julian W, et al.
Publicado: (2021)

What Is New With Omicron Variant of SARS-CoV-2 in Children?
por: Bittmann, Stefan, et al.
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023)

Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses
por: Anft, Moritz, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?
por: Ricco, Matteo, et al.
Publicado: (2021)

Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses
por: Halfmann, Peter J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_es2jq8r0d47jo3o130k0qmlqke